Clinical Trial

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Study acronym: SPARE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-04-18; most recent amendment 2026-04-02.
Status change: Not Yet Recruiting → Recruiting 2025-03-25
Trial Details
NCT Number NCT06376669
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: Robert L. Sloan Fund for Cancer Research
Conditions Renal Cell Carcinoma
Enrollment 20 participants
Start Date 2025-02-25
Primary Completion 2027-06 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-03